Raghvendra M. Srivastava, Ph.D., is an Assistant professor at Cleveland Clinic Lerner College of Medicine, and director of the Discovery lab at Center for Immunotherapy and Precision Immuno-Oncology (CITI). Dr. Srivastava has been a Research Instructor (faculty) at the University of Pittsburgh Hillman Cancer Center. and Senior Scientist in Immunogenomics laboratory under Dr. Timothy A. Chan at MSKCC and ran Immunological operations and several collaborative cancer immunology projects. His doctorate in cancer immunology and more than 12 years of experience in the field of cancer antigens and diverse Immuno-Oncology puts him in a unique position to run collaborative laboratory and cancer immunology projects. As a basic/translational cancer immunology laboratory, he is uniquely positioned to investigate mechanisms of anti-tumor immunity in the tumor microenvironment, as well as, discover tumor cell escape mechanisms in a wide variety of cancer types. In these capacities, Dr. Srivastava facilitates and enhances the development of new targets, decipher novel genomic mechanisms of actions of immunomodulatory drugs, and develops novel therapeutic agents through collaborative, trans-disciplinary preclinical research and clinical application at Cleveland Clinic.
Dr. Srivastava focuses on using high-throughput immunological methods and several next-generation single-cell sequencing technology platforms to unravel genomic determinants of cancer immunotherapy. He has published several papers focused on the development of cancer antigens, neoantigens, and establishing precision-based cancer immunotherapy programs for patients. His primary research area includes the understanding of the mechanism of action of FDA-approved immune checkpoint inhibitors on T cell responses and defining the role of genetic mutations in oncogenesis, neoantigens generation, and cancer recognition and elimination. These strategies help in patient selection criteria and enhance the efficacy of FDA-approved immune checkpoint inhibitors.